Q-omics provides the consensus-scored TFF3 profile across patient tissues and cancer cell-line models. TFF3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TFF3 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, TFF3 RNA expression shows 18,033 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, THCA, and BRCA as cancer lineages where TFF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFF3 survival associations across molecular data types. TFF3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFF3 RNA expression–survival associations across cancer types. High TFF3 expression shows unfavorable associations in LGG, ESCA and KIRP, but favorable associations in UVM, UCEC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TFF3 RNA expression.
This table summarizes TFF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TFF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFF3 shows lower tumor expression in THCA, HNSC, KIRC, KICH and KIRP and higher tumor expression in BRCA. The THCA box plot shows higher TFF3 RNA expression in normal versus tumor tissue (log2 FC = −9.627, t-test p < 0.001).
This table shows molecular features associated with TFF3 in patient tissues and cancer cell lines. In patient samples, TFF3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TFF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
